

**THRU ONLINE FILING**

October 16, 2023

BSE Ltd.  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai 400 023  
Scrip Code – 524494

National Stock Exchange India Limited,  
Exchange Plaza, C-1, Block-G,  
Bandra Kurla Complex, Bandra – (East).  
Mumbai-400051.  
Scrip Code : IPCALAB

Dear Sir,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that Mr. Hitesh Kumar Maheshwari has joined the Company as President – R&D (Formulations) with effect from 16<sup>th</sup> October, 2023.

Details of the appointee pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

<b>Name : Mr. Hitesh Kumar Maheshwari, President – R&amp;D (Formulations)</b>		
1.	Reason for Change	Appointed as President – R&D (Formulations)
2.	Date of appointment & term of appointment	16 <sup>th</sup> October, 2023
3.	Brief Profile (in case of appointment)	Mr. Hitesh Maheshwari, aged 49 years has completed his B. Pharm from Devi Ahilya Vishwavidyalaya, Indore and M.Pharm from Panjab University, Chandigarh. Mr. Maheshwari brings with him a professional experience of over 24 years. He started his career with Ranbaxy Laboratories in the year 1999 and thereafter worked with Zydus Cadila Healthcare Ltd., Hikma Pharmaceuticals Ltd., Astron Research Ltd. and Macleods Pharmaceuticals Ltd. Prior to joining us, he was associated with Torrent Pharmaceuticals Ltd. as Executive Director and Head – R&D (Formulations). He will be responsible for leading all the activities related to the Research & Development (Formulations) Division of the Company
4.	Disclosure of relationships between directors	He is not related to any Director or Key Managerial Personnel of the Company.

Thanking you

Yours faithfully  
For Ipca Laboratories Limited

Harish Kamath  
Corporate Counsel & Company Secretary

Ipca Laboratories Ltd.  
[www.ipca.com](http://www.ipca.com)